ERS Respiratory Channel

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

Abstract

Introduction

There is lack of evidence regarding the real-life treatment patterns in chronic obstructive pulmonary disease (COPD) and the characteristics of patients who initiate triple therapies (TT).

Aims

To describe the demographics and clinical characteristics of 4 groups of patients initiating TT in the MDV claims database in a period of May 2018 to December 2021: (1) early adopters (within the first 12 months after market approval) of budesonide/glycopyrronium/formoterol (BGF), (2) contemporary BGF users (from 12-month after market approval); (3) fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI); and (4) any multiple-inhaler triple therapy (MITT).

Results

Overall, 636 patients were BGF early adopters, 2,558 contemporary BGF users, 11,187 were on FF/UMEC/VI, and 5,931 on MITT. During the baseline period, at least one moderate/severe exacerbation was observed in 18.2% of BGF early adopters, 14.3% of the BGF contemporary users, 13.1% of patients on FF/UMEC/VI and 14.0% of patients on MITT. The proportion of asthma+COPD tended to be higher in users of MITT (84.5%) compared to early adopters (73.0%), BGF contemporary cohort (74.2%), and FF/UMEC/VI (75.7%). ICS/LABA, LABA/LAMA, and LAMA alone were the three most frequent prior maintenance treatments received, respectively, for 38.2%, 31.1%, and 23.0% of early BGF adopters, and for 40.9%, 26.0%, and 25.6% of contemporary BGF patients.

Conclusions

The proportion of asthma+COPD patients was high among those initiating TT, especially MITT. Patients using BGF in the first 12 months after market approval had a higher history of exacerbations.

Abstract

#{title}